Health Insurance Report™ helps you track and analyze legal, legislative, and regulatory developments affecting the health-insurance industry throughout implementation of the Affordable Care Act...
Two groups representing pharmacies urged the Federal Trade Commission to oppose a merger of pharmacy benefit managers Express Scripts Inc. and Medco Health Solutions Inc.
The Aug. 3 letter from the National Association of Chain Drug Stores (NACDS) and the National Community Pharmacists Association (NCPA) said the PBMs' merger would result in a consolidated company with “excessive market power that will have anticompetitive effects on patients and the healthcare delivery system.”
Meanwhile, the top Democrat on the House Judiciary Committee Aug. 5 called for a hearing on the proposed merger.
Rep. John Conyers Jr. (D-Mich.) said in a letter to Judiciary Chairman Lamar Smith (R-Texas) that the committee should examine how the merger would affect competition in the prescription drug benefit and pharmacy market.
The pharmacy groups told FTC that their opposition “stems from the fact that the merger would result in a substantial reduction of competition in already highly-concentrated markets, including those involving PBM services, as well as mail order distribution services and specialty pharmaceutical services.” Such a merger would control a “large share of the supply line for brand and generic prescription drugs, and thereby will have the ability to raise prices to plans and patients, and limit access to pharmacy patient care.”
Medco and Express Scripts announced the merger in late July, at which time NACDS and NCPA announced their opposition (see previous article). Under the merger agreement, Express Scripts would buy Medco for $29.1 billion. The companies said they expect the transaction to close in the first half of 2012.
NACDS and NCPA offered to assist FTC in its assessment, examination, and investigation into the merger's anti-competitive nature and its consequences on patient access and consumer care.
Express Scripts said Aug. 4 in a statement that it is “proud of the relationships it has built over the past 25 years with pharmacies of every type.”
“We work closely with retail pharmacies of every size to negotiate contracts that are beneficial to all parties,” Express Scripts said. “We will continue to support the growth and expansion of independent pharmacies in our networks. Our goal is to make sure patients have access to the medications they need at the best possible price in all settings.”
In July, George Paz, chairman and CEO of Express Scripts, said “the merger with Medco will accelerate our efforts to create greater efficiencies in the healthcare system and better protect American families from the rising costs of prescription medicine while improving health outcomes.”
The pharmacy groups' letter is available at http://www.nacds.org/user-assets/pdfs/2011/newsrelease/8_3_FTC.pdf . Conyers' letter is at http://op.bna.com/hl.nsf/r?Open=sbar-8kjskq .
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)